https://orcid.org/0000-0002-5007-9509
References
- Our World In Data.org . Mortality risk of Covid-19. (2020). https://ourworldindata.org/coronavirus
- Rockx B , KuikenT, HerfstSet al. Comparative pathogenesis of COVID-19, MERS and SARS in a nonhuman primate model. Science, 368(6494), 1012–1015 (2020).
- Zhou F , YuT, DuRet al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395(10229), 1011–1088 (2020).
- Mayran A , SochodolskyK, KhetchoumianKet al. Pioneer and nonpioneer factor cooperation drives lineage specific chromatin opening. Nat. Commun., 10(1), 3807–3020 (2019).
- Bertola DR , HonjoRS, BaratelaWAR. Stüve–Wiedemann syndrome: update on clinical and genetic aspects. Mol. Syndromol., 7(1), 12–18 (2016).
- Quinton LJ , MizgerdJP, HilliardKL, JonesMR, KwonCY, AllenE. Leukemia inhibitory factor signaling is required for lung protection during pneumonia. J. Immunol., 188(12), 6300–6308 (2012).
- Foronjy RF , DaboAJ, CumminsN, GeraghtyP. Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection. BMC Immunol., 15(1), 41–56 (2014).
- Ulich TR , FannMJ, PattersonPHet al. Intratracheal injection of LPS and cytokines. V. LPS induces expression of LIF and LIF inhibits acute inflammation. Am. J. Physiol., 267(4 Pt 1), L442–L426 (1994).
- Rolfe BE , StamatiouS, CameronJet al. Leukaemia inhibitory factor retards the progression of atherosclerosis. Cardiovasc. Res., 58(1), 222–230 (2003).
- Becker RC . COVID-19-associated vasculitis and vasculopathy. J. Thromb. Thrombolysis, 50(3), 499–511 (2020).
- Barkauskas CE , CronceMJ, RackleyCRet al. Type 2 alveolar cells are stem cells in adult lung. J. Clin. Invest., 123(7), 3025–3036 (2013).
- Zhao Y , ZhaoZ, WangY, ZhouY, MaY, ZuoW. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am. J. Respir. Crit. Care Med., 202(5), 756–759 (2020).
- Traber KE , SymerEM, AllenEet al. Myeloid-epithelial cross talk coordinates synthesis of the tissue-protective cytokine leukemia inhibitory factor during pneumonia. Am. J. Phys. Lung Cell. Mol. Phys., 313(3), L548–L558 (2017).
- Knight D . Leukaemia inhibitory factor (LIF): a cytokine of emerging importance in chronic airway inflammation. Pulm. Pharmacol. Ther., 14(3), 169–176 (2001).
- Correll KA , EdeenKE, ZemansRLet al. Transitional human alveolar type II epithelial cells suppress extracellular matrix and growth factor gene expression in lung fibroblasts. Am. J. Physiol. Lung Cell. Mol. Physiol., 317(2), L283–L294 (2019).
- Gao W , ThompsonL, ZhouQet al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle, 8(9), 1444–1450 (2009).
- Park J , GaoW, WhistonR, StromTB, MetcalfeS, FahmyTM. Modulation of CD4 T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol. Pharm., 8(1), 143–152 (2011).
- Davis ID , KiersL, MacGregorLet al. A randomized, double-blinded, placebo-controlled Phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, Emfilermin, AM424) to prevent chemotherapy induced peripheral neuropathy. Clin. Cancer Res., 11(5), 1890–1898 (2005).
- Metcalfe SM . Mesenchymal stem cells and management of COVID-19 pneumonia. Med. Drug Discov., 5, 100019 (2020).
- Cao W , YangY, WangZet al. Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity, 35(2), 1–12 (2011).